All In Biotech

Drug Trial Radar · NCT06667908

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Dec 6, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • JNJ-90301900Drug

    JNJ-90301900 will be injected intratumorally and/or intranodally.

  • DurvalumabBiological

    Durvalumab will be administered as intravenous (IV) infusion as cIT.

  • Concurrent Chemo/Radiation Therapy (cCRT)Radiation

    Radiation by intensity modulated radiation therapy (IMRT) will be administered.

  • Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinDrug

    Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

  • Concurrent Chemo/Radiation Therapy (cCRT): PaclitaxelDrug

    Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Using Independent Central Review (ICR) AssessmentTime frame: Up to 2 Years and 2 months

Locations

45 sites in 10 countries. Site status is shown where the registry gives one.

  • Moores Cancer Center at UC San Diego Health

    La Jolla, California · Recruiting

  • University of Connecticut Health Center

    Farmington, Connecticut · Completed

  • Yale University

    New Haven, Connecticut · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Washington University in St Louis

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • FirstHealth of the Carolinas

    Pinehurst, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Oregon Health And Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Vermont Medical Center

    Burlington, Vermont · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Australia · Recruiting

  • Sir Charles Gairdner Hospital

    Nedlands, Australia · Recruiting

  • Macquarie University

    North Ryde, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Australia · Recruiting

  • Fundacao Pio XII

    Barretos, Brazil · Recruiting

  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes

    São Paulo, Brazil · Recruiting

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil · Recruiting

  • Dongguan People s Hospital

    Dongguan, China · Recruiting

  • The First Affiliated Hospital Sun Yat sen University

    Guangzhou, China · Recruiting

  • The Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

  • Hopital De La Cavale Blanche

    Brest, France · Recruiting

  • Hopital Nord Marseille

    Marseille, France · Recruiting

  • Hopital Tenon

    Paris, France · Recruiting

  • Institut Curie

    Paris, France · Recruiting

  • CHU Rouen Hopital Charles Nicolle

    Rouen, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Prince of Wales Hospital

    Shatin, Hong Kong · Recruiting

  • Antoni van Leeuwenhoek

    Amsterdam, Netherlands · Recruiting

  • Radboud Umcn

    Nijmegen, Netherlands · Recruiting

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain · Recruiting

  • Clinica Univ. de Navarra

    Pamplona, Spain · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.